CL2008003808A1 - Componente de vacuna contra la malaria que comprende una particula inmunogena rts,s y/o una particula que se deriva de la proteina cs de una o mas cepas de p. vivax y el antigeno s de la hepatitis b o una particula inmunogena que comprende rts, csv-s y opcionalmente el antigeno s sin fusionar y un agente estabilizante ; y vacuna. - Google Patents
Componente de vacuna contra la malaria que comprende una particula inmunogena rts,s y/o una particula que se deriva de la proteina cs de una o mas cepas de p. vivax y el antigeno s de la hepatitis b o una particula inmunogena que comprende rts, csv-s y opcionalmente el antigeno s sin fusionar y un agente estabilizante ; y vacuna.Info
- Publication number
- CL2008003808A1 CL2008003808A1 CL2008003808A CL2008003808A CL2008003808A1 CL 2008003808 A1 CL2008003808 A1 CL 2008003808A1 CL 2008003808 A CL2008003808 A CL 2008003808A CL 2008003808 A CL2008003808 A CL 2008003808A CL 2008003808 A1 CL2008003808 A1 CL 2008003808A1
- Authority
- CL
- Chile
- Prior art keywords
- rts
- antigen
- immunogenic particle
- vaccine
- vivax
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Componente de vacuna contra la malaria que comprende una partícula inmunogena rts,s y/o una partícula que se deriva de la proteina cs de una o más cepas de p. Vivax y el antígeno s de la hepatitis b o una partícula inmunogena que comprender ts, csv-s y opcionalmente el antígeno s sin fusionar y un agente estabilizante; y vacuna.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1576207P | 2007-12-21 | 2007-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008003808A1 true CL2008003808A1 (es) | 2011-03-11 |
Family
ID=40584700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008003808A CL2008003808A1 (es) | 2007-12-21 | 2008-12-18 | Componente de vacuna contra la malaria que comprende una particula inmunogena rts,s y/o una particula que se deriva de la proteina cs de una o mas cepas de p. vivax y el antigeno s de la hepatitis b o una particula inmunogena que comprende rts, csv-s y opcionalmente el antigeno s sin fusionar y un agente estabilizante ; y vacuna. |
Country Status (22)
Country | Link |
---|---|
US (1) | US20100272745A1 (es) |
EP (1) | EP2234637A2 (es) |
JP (1) | JP2011507816A (es) |
KR (1) | KR20100109556A (es) |
CN (1) | CN102026657A (es) |
AP (1) | AP2010005296A0 (es) |
AR (1) | AR071741A1 (es) |
AU (1) | AU2008339980A1 (es) |
BR (1) | BRPI0822098A2 (es) |
CA (1) | CA2708716A1 (es) |
CL (1) | CL2008003808A1 (es) |
CO (1) | CO6300963A2 (es) |
CR (1) | CR11577A (es) |
DO (1) | DOP2010000189A (es) |
IL (1) | IL206308A0 (es) |
MA (1) | MA32030B1 (es) |
MX (1) | MX2010006984A (es) |
PE (1) | PE20091528A1 (es) |
TW (1) | TW200940086A (es) |
UY (1) | UY31569A1 (es) |
WO (1) | WO2009080715A2 (es) |
ZA (1) | ZA201004304B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013142278A1 (en) * | 2012-03-22 | 2013-09-26 | New York University | Plasmodium vivax vaccine compositions |
WO2016184784A1 (en) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1 |
IL286493B (en) | 2015-11-06 | 2022-07-01 | Memorial Sloan Kettering Cancer Center | Triterpene saponin analogs, methods for their production, preparations containing them and their uses |
CN105233296B (zh) * | 2015-11-24 | 2018-08-17 | 江苏省农业科学院 | 用于鸭病毒性肝炎活疫苗的耐热冻干保护剂及其制备方法和应用 |
GB201608821D0 (en) | 2016-05-19 | 2016-07-06 | Isis Innovation | Vaccines |
JP7177082B2 (ja) * | 2017-04-25 | 2022-11-22 | アジュバンス・テクノロジーズ・インコーポレーテッド | トリテルペンサポニン類似物 |
CA3061205A1 (en) * | 2017-04-25 | 2018-11-01 | Adjuvance Technologies, Inc. | Triterpene saponin analogues |
CA3075822A1 (en) | 2017-10-16 | 2019-04-25 | Adjuvance Technologies, Inc. | Triterpene saponin analogues |
EP3947446A1 (en) | 2019-03-25 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of taupathy disorders by targeting new tau species |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8819209D0 (en) * | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
CA2075521C (en) * | 1992-05-05 | 1995-11-28 | Kuniaki Koyama | Stabilized live vaccine |
ATE285239T1 (de) * | 1996-04-26 | 2005-01-15 | Merck & Co Inc | Dna enthaltende impfstoffen |
ZA973642B (en) * | 1996-04-26 | 1997-11-25 | Merck & Co Inc | DNA vaccine formulations. |
GB9616351D0 (en) * | 1996-08-02 | 1996-09-11 | Smithkline Beecham Biolog | Vaccine composition |
WO1999011241A1 (en) * | 1997-09-05 | 1999-03-11 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
JP2003500456A (ja) * | 1999-06-02 | 2003-01-07 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 角質細胞増殖因子−2製剤 |
US20070141086A1 (en) * | 2003-11-21 | 2007-06-21 | Ohara Michael K | Use of antibiotics as vaccine adjuvants |
SG183683A1 (en) * | 2004-02-02 | 2012-09-27 | Tanox Inc | Identification of novel ige epitopes |
GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
EP1962910A4 (en) * | 2005-12-15 | 2010-03-31 | Aeras Global Tb Vaccine Found | NEW PRIME BOOST COMBINATION FROM WEAKEN MYCOBACTERIA |
TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
-
2008
- 2008-12-18 CN CN2008801272415A patent/CN102026657A/zh active Pending
- 2008-12-18 JP JP2010538733A patent/JP2011507816A/ja active Pending
- 2008-12-18 CL CL2008003808A patent/CL2008003808A1/es unknown
- 2008-12-18 AU AU2008339980A patent/AU2008339980A1/en not_active Abandoned
- 2008-12-18 US US12/809,727 patent/US20100272745A1/en not_active Abandoned
- 2008-12-18 EP EP08864235A patent/EP2234637A2/en not_active Withdrawn
- 2008-12-18 BR BRPI0822098-0A patent/BRPI0822098A2/pt not_active IP Right Cessation
- 2008-12-18 AP AP2010005296A patent/AP2010005296A0/en unknown
- 2008-12-18 MX MX2010006984A patent/MX2010006984A/es not_active Application Discontinuation
- 2008-12-18 CA CA2708716A patent/CA2708716A1/en not_active Abandoned
- 2008-12-18 KR KR1020107016404A patent/KR20100109556A/ko not_active Application Discontinuation
- 2008-12-18 WO PCT/EP2008/067925 patent/WO2009080715A2/en active Application Filing
- 2008-12-19 UY UY31569A patent/UY31569A1/es unknown
- 2008-12-19 TW TW097149849A patent/TW200940086A/zh unknown
- 2008-12-19 AR ARP080105601A patent/AR071741A1/es not_active Application Discontinuation
- 2008-12-19 PE PE2008002169A patent/PE20091528A1/es not_active Application Discontinuation
-
2010
- 2010-06-10 IL IL206308A patent/IL206308A0/en unknown
- 2010-06-11 CO CO10071045A patent/CO6300963A2/es not_active Application Discontinuation
- 2010-06-17 ZA ZA2010/04304A patent/ZA201004304B/en unknown
- 2010-06-18 DO DO2010000189A patent/DOP2010000189A/es unknown
- 2010-07-19 MA MA33035A patent/MA32030B1/fr unknown
- 2010-07-21 CR CR11577A patent/CR11577A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MA32030B1 (fr) | 2011-01-03 |
EP2234637A2 (en) | 2010-10-06 |
TW200940086A (en) | 2009-10-01 |
BRPI0822098A2 (pt) | 2015-06-30 |
AR071741A1 (es) | 2010-07-14 |
WO2009080715A3 (en) | 2009-11-12 |
UY31569A1 (es) | 2009-08-03 |
CA2708716A1 (en) | 2009-07-02 |
KR20100109556A (ko) | 2010-10-08 |
DOP2010000189A (es) | 2010-08-15 |
AP2010005296A0 (en) | 2010-06-30 |
PE20091528A1 (es) | 2009-10-29 |
US20100272745A1 (en) | 2010-10-28 |
JP2011507816A (ja) | 2011-03-10 |
IL206308A0 (en) | 2010-12-30 |
CN102026657A (zh) | 2011-04-20 |
WO2009080715A2 (en) | 2009-07-02 |
ZA201004304B (en) | 2012-11-28 |
CO6300963A2 (es) | 2011-07-21 |
CR11577A (es) | 2010-09-03 |
AU2008339980A1 (en) | 2009-07-02 |
MX2010006984A (es) | 2010-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008003808A1 (es) | Componente de vacuna contra la malaria que comprende una particula inmunogena rts,s y/o una particula que se deriva de la proteina cs de una o mas cepas de p. vivax y el antigeno s de la hepatitis b o una particula inmunogena que comprende rts, csv-s y opcionalmente el antigeno s sin fusionar y un agente estabilizante ; y vacuna. | |
CL2018003520A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. | |
BR112015023391A2 (pt) | formulações compreendendo conjugado droga-anticorpo anti-egfr | |
MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
EA201291105A1 (ru) | Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора | |
ATE426412T1 (de) | Adjuvante influenza-vakzine | |
CU20150018A7 (es) | Composición para el tratamiento de la infección por hepatitis b o coinfección por hepatitis b/hepatitis d | |
CO2019011640A2 (es) | Métodos y composiciones para la reducción de la inmunogenicidad | |
ECSP066662A (es) | Preparación farmacéutica que comprende un anticuerpo contra el receptor egf | |
WO2017214458A3 (en) | Anti-cd98 antibodies and antibody drug conjugates | |
WO2017214462A3 (en) | Anti-cd98 antibodies and antibody drug conjugates | |
CR11307A (es) | Vacunas | |
CR20160041A (es) | Proteína de fusión terapéutica | |
BR112018075630A2 (pt) | anticorpos anti-cd98 e conjugados de fármaco de anticorpo | |
JP2019520863A5 (es) | ||
ECSP10010056A (es) | ANTICUERPOS ANTI-IL-12/23p40, EPÍTOPES, FORMULACIONES, COMPOSICIONES, MÉTODOS Y USOS | |
AR098168A1 (es) | Formulación estable de insulina glulisina | |
CY1110744T1 (el) | Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c | |
CL2019002133A1 (es) | Partícula similar a virus (vlp). | |
WO2007016715A3 (en) | Immune response inducing preparations | |
ATE471990T1 (de) | Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln | |
CL2008003875A1 (es) | Particula proteínica inmunógena que comprende una proteína de fusión que comprende secuencias derivadas de una proteina cs de p. vivax y el antigeno s de la hepatitis b y el antigeno s derivado del virus de la hepatitis b; composicion farmaceutica que lo comprende; procedimiento de producción; y su uso para tratar malaria. | |
EA201200538A1 (ru) | Арабиногалактан для повышения приобретенного иммунного ответа | |
MX2020003753A (es) | Composicion nasal de vacuna contra hepatitis b y metodo para producir la misma. |